New Mesothelioma Research Reveals Survival Advantage with Repeat CRS/HIPEC, Reports Surviving Mesothelioma - 47 ABC - Delmarva's Choice

New Mesothelioma Research Reveals Survival Advantage with Repeat CRS/HIPEC, Reports Surviving Mesothelioma


This article was originally distributed via PRWeb. PRWeb, WorldNow and this Site make no warranties or representations in connection therewith.


Peritoneal mesothelioma patients who undergo surgery and heated chemotherapy more than once may safely improve their odds of survival.

Raleigh, NC (PRWEB) August 17, 2014

A new study conducted by a team of Washington, DC mesothelioma surgeons finds that peritoneal mesothelioma patients who have a combination of cytoreductive surgery and heated chemotherapy (CRS/HIPEC) again when cancer comes back have better outcomes and few serious complications. Click here to read the full story now on the Surviving Mesothelioma website.

Mesothelioma surgeon Dr. Paul Sugarbaker and colleagues with the Program in Peritoneal Surface Oncology analyzed the outcomes of 205 consecutive CRS/HIPEC procedures for mesothelioma, 44 of which were repeat procedures.

Iterative [repeat] CRS and HIPEC can be performed safely and appear to have benefits with this group of patients showing an improved median survival, writes Dr. Sugarbakers colleague and lead author on the study, Chukwuemeka Ihemelandu, MD.

The study, published in the Annals of Surgical Oncology, found a complication rate among repeat CRS/HIPEC patients of just 2.3% and no deaths within 30 days of surgery.

We know that CRS and HIPEC can improve survival in peritoneal mesothelioma, but we also know that, in almost all cases, that cancer will start growing again, says Alex Strauss, Managing Editor of Surviving Mesothelioma. This study is potentially very good news for patients in that situation.

To better understand the study and read more detailed results, see Repeat CRS/HIPEC Improves Survival for Peritoneal Mesothelioma now available on the Surviving Mesothelioma website.

Ihemelandu, C, Iterative Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy or Recurrent or Progressive Diffuse Malignant Peritoneal Mesothelioma: Clinicopathologic Characteristics and Survival Outcome, August 14, 2014, Annals of Surgical Oncology, Epub ahead of print,

For nearly ten years, Surviving Mesothelioma has brought readers the most important and ground-breaking news on the causes, diagnosis and treatment of mesothelioma. All Surviving Mesothelioma news is gathered and reported directly from the peer-reviewed medical literature. Written for patients and their loved ones, Surviving Mesothelioma news helps families make more informed decisions.

For the original version on PRWeb visit:

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact

Powered by WorldNow
Powered by WorldNow All content © Copyright 2000 - 2014 WorldNow and WMDT. All Rights Reserved. For more information on this site, please read our Privacy Policy and Terms of Service.